North Carolina is currently home to 2657 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
NCT06315738
Recruiting
The primary objective of this study is to determine the safety and tolerability of two dose levels (0.5 mL/kg and 1.0 mL/kg) of once daily (QD) via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC by incidence of treatment emergent adverse events (TEAEs) and SAEs, with a secondary objective to assess preliminary efficacy of the same two dose levels (0.5 mL/kg and 1.0 mL/kg) of QD via IV route of administration of ST266 in treating patients with... Read More
Gender:
ALL
Ages:
Between 2 weeks and 8 weeks
Trial Updated:
05/19/2025
Locations: Duke University Medical Center (DUMC), Durham, North Carolina
Conditions: Necrotizing Enterocolitis
Register for Updates
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
NCT06305806
Recruiting
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: All sites listed under NCT06305780, Durham, North Carolina
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
NCT06305793
Recruiting
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: All sites listed under NCT06305780, Durham, North Carolina
Conditions: Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Register for Updates
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705
Recruiting
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA rel... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/19/2025
Locations: West Clinical Research, Morehead City, North Carolina
Conditions: Glenohumeral Osteoarthritis
Register for Updates
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Clinical Study Site, Raleigh, North Carolina
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
NCT06043674
Recruiting
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Chronic Lymphocytic Leukemia, Richter's Transformation
Register for Updates
Liver Cirrhosis Network Cohort Study
NCT05740358
Recruiting
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Duke Liver Center, Durham, North Carolina
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT05472792
Recruiting
The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or endocrine therapy alone after lumpectomy. The study population will include women age 65 years and older with low-risk tumor characteristics (tumor size \<2cm, grade 1-2, node-negative). APBI will consist of 5 fractions of radiation therapy delivered every other day to the l... Read More
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
05/19/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Quality of Life
Register for Updates
R21: An Easy-to-use, iNtelligent, Affordable LinEr (ENABLE) System for Socket Fit Assessment
NCT05425810
Recruiting
Lower limb amputees (LLA) rely on their prosthetic legs to remain active and lead an independent life. For most LLAs, a well-fitted prosthetic socket is the only option to interface with their prosthetic leg, however, it is a real challenge to make a prosthetic socket to interface with residual limbs accurately. One of the reasons is that there lack of accurate approaches to evaluate the pressure distribution on the residual limb accurately and effectively. To overcome this issue, the research t... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/19/2025
Locations: NC State University, Raleigh, North Carolina
Conditions: Lower Limb Amputation Below Knee (Injury)
Register for Updates
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
NCT05055609
Recruiting
TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than normal cells to perturbations in nucleotide metabolism by DNA-targeting treatments such as TRE-515. The Primary objective is to determine the safety and maximum tolerability of TRE-515 when administere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Carolina BioOncology Institute, Huntersville, North Carolina
Conditions: Solid Tumor, Adult, Oncology
Register for Updates
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
NCT04918173
Recruiting
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
05/19/2025
Locations: Duke University, Durham, North Carolina
Conditions: Congenital Antithrombin Deficiency
Register for Updates